Correction to: Long-term neurocognitive functioning of children treated with propranolol or atenolol for infantile hemangioma (European Journal of Pediatrics, (2022), 182, 2, (757-767), 10.1007/s00431-022-04674-7)

In the original published version of the above article, the data reported with ‘yes’ and ‘no’ under "Child migration background" are switched up. The Table 1 below is the correct listing. (Table presented.) Participant characteristics All (n = 105) Propranolol (n = 36) Atenolol (n = 69) p-value Child age, years Median (IQR) 7.4 (6.7–8.5) 8.0 (7.3–8.8) 7.1 (6.4–8.1) < 0.001 Range 6.0–11.8 6.4–11.8 6.0–9.7 Child sex, n (%) Female 85 (81) 29 (81) 56 (81) > 0.99 Male 20 (19) 7 (19) 13 (19) Child migration background ^a, n (%) Yes 10 (10) 0 (0.0) 10 (14) 0.01 No 94 (90) 36 (100) 58 (84) Unknown 1 (1.0) 0 (0.0) 1 (1.4) Education mother, n (%) Low 14 (13) 6 (17) 8 (12) 0.89 Average 28 (27) 8 (22) 20 (29) High 62 (59) 22 (61) 40 (58) Unknown 1 (1.0) 0 (0.0) 1 (1.4) Home language, n (%) Dutch 97 (92) 35 (97) 62 (90) 0.37 Other 2 (2.0) 0 (0.0) 2 (2.9) Multilingual 6 (5.7) 1 (2.8) 5 (7.2) Confirmed diagnosis, n (%) Attention deficit/hyperactivity disorder 6 (5.7) 3 (8.3) 3 (4.3) Location of IH ^b, n (%) Head and neck 84 (80) 24 (67) 60 (87) 0.02 Trunk 13 (12) 6 (17) 7 (10) 0.36 Genital area 13 (12) 7 (19) 6 (8.7) 0.13 Extremities 7 (6.7) 3 (8.3) 4 (5.8) 0.69 Ulcerated IH, n (%) Yes 29 (28) 13 (36) 16 (23) 0.16 No 76 (72) 23 (64) 53 (77) Treatment center, n (%) Erasmus MC 34 (32) 31 (86) 3 (4.3) < 0.001 UMCU 71 (68) 5 (14) 66 (96) Age at treatment initiation, months Median (IQR) 3.5 (2.2–5.1) 3.6 (2.2–5.3) 3.4 (2.2–5.0) 0.58 Range 0.92–11.4 1.64–11.4 0.92–10.9 Treatment duration, months Median (IQR) 13.8 (10.9–19.4) 18.6 (12.5–22.7) 13.0 (10.4–15.8) 0.001 Range 6.41–62.7 9.13–62.7 6.41–56.8 Average dose, mg/kg/day Median (IQR) 1.2 (1.0–1.8) 1.9 (1.8–2.0) 1.0 (1.0–1.2) < 0.001 Range 0.8–2.5 1.4–2.5 0.8–2.0 Peak dose, mg/kg/day Median (IQR) 1.6 (1.0–2.1) 2.1 (2.0–2.3) 1.0 (1.0–1.6) < 0.001 Range 1.0–14.0 1.9–14.0 1.0–3.0 Cumulative dose, mg/kg Median (IQR) 577.4 (387.2–881.7) 1122.7 (718.6–1282.3) 418.7 (310.0–619.7) < 0.001 Range 186.6–3544 494.1–3544 186.6–2206 Follow-up time ^c, years Median (IQR) 5.9 (5.2–6.5) 6.2 (5.6–6.6) 5.7 (5.1–6.2) 0.13 Range 1.6–9.7 1.6–9.7 4.5–8.4 p values indicate differences in participant characteristics between propranolol and atenolol group Continuous variables were not normally distributed and analyzed with a Mann-Whitney U test. Dichotomous variables were analyzed with a Fisher’s exact test ^aChild migration background, categorized as “yes” = one or both parents born abroad or “no” = both parents born in the Netherlands ^bA total of 105 patients had a total of 128 IH. The variable “location of IH” represents the number of children with at least one infantile hemangioma at each region ^cFollow-up time: time interval between cessation of beta-blocker treatment and neuropsychological assessment The original article has been corrected.